[go: up one dir, main page]

NO20090235L - Kondenserte sykliske forbindelser - Google Patents

Kondenserte sykliske forbindelser

Info

Publication number
NO20090235L
NO20090235L NO20090235A NO20090235A NO20090235L NO 20090235 L NO20090235 L NO 20090235L NO 20090235 A NO20090235 A NO 20090235A NO 20090235 A NO20090235 A NO 20090235A NO 20090235 L NO20090235 L NO 20090235L
Authority
NO
Norway
Prior art keywords
cyclic compounds
condensed cyclic
compound
salt
prodrug
Prior art date
Application number
NO20090235A
Other languages
English (en)
Norwegian (no)
Inventor
Tsuneo Yasuma
Nobuyuki Negoro
Masayuki Mashita
Masahiro Itou
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20090235L publication Critical patent/NO20090235L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
NO20090235A 2006-06-27 2009-01-14 Kondenserte sykliske forbindelser NO20090235L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006177099 2006-06-27
PCT/JP2007/063208 WO2008001931A2 (en) 2006-06-27 2007-06-26 Fused cyclic compounds

Publications (1)

Publication Number Publication Date
NO20090235L true NO20090235L (no) 2009-02-16

Family

ID=38656568

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090235A NO20090235L (no) 2006-06-27 2009-01-14 Kondenserte sykliske forbindelser

Country Status (37)

Country Link
US (5) US7732626B2 (ja)
EP (4) EP2248812B1 (ja)
JP (3) JP4401428B2 (ja)
KR (1) KR101058772B1 (ja)
CN (4) CN102731451B (ja)
AR (1) AR061644A1 (ja)
AT (1) ATE543815T1 (ja)
AU (1) AU2007265966B2 (ja)
BR (1) BRPI0713378A8 (ja)
CA (2) CA2838448A1 (ja)
CL (1) CL2007001873A1 (ja)
CO (1) CO6160234A2 (ja)
CR (1) CR10564A (ja)
CY (2) CY1112705T1 (ja)
DK (2) DK2248812T5 (ja)
ES (2) ES2450081T3 (ja)
GE (1) GEP20115359B (ja)
HK (1) HK1131126A1 (ja)
HR (2) HRP20120333T1 (ja)
IL (1) IL195947A (ja)
JO (1) JO2969B1 (ja)
MA (1) MA30537B1 (ja)
ME (1) ME00535B (ja)
MX (1) MX2008016274A (ja)
MY (1) MY154798A (ja)
NO (1) NO20090235L (ja)
NZ (1) NZ574038A (ja)
PE (1) PE20080993A1 (ja)
PL (2) PL2041123T3 (ja)
PT (2) PT2248812E (ja)
RS (2) RS53230B (ja)
RU (1) RU2444521C2 (ja)
SI (2) SI2248812T1 (ja)
TW (1) TWI354668B (ja)
UA (1) UA95296C2 (ja)
WO (1) WO2008001931A2 (ja)
ZA (1) ZA200900154B (ja)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008311355B2 (en) 2007-10-10 2012-01-19 Amgen Inc. Substituted biphenyl GPR40 modulators
JP2011515341A (ja) * 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
WO2009117421A2 (en) * 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2313360B1 (en) 2008-07-28 2012-09-05 Syddansk Universitet Compounds for the treatment of metabolic diseases
TW201014850A (en) 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
MX2011003917A (es) 2008-10-15 2011-05-31 Amgen Inc Moduladores de grp40 espirociclicos.
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
JPWO2010076884A1 (ja) 2008-12-29 2012-06-21 武田薬品工業株式会社 新規縮合環化合物およびその用途
EP2382218A1 (en) 2009-01-27 2011-11-02 Takeda Pharmaceutical Company Limited Delta-5-desaturase inhibitors
WO2010123016A1 (ja) 2009-04-22 2010-10-28 アステラス製薬株式会社 カルボン酸化合物
US20120172351A1 (en) 2009-06-09 2012-07-05 Nobuyuki Negoro Novel fused cyclic compound and use thereof
IN2012DN00954A (ja) 2009-07-28 2015-04-10 Takeda Pharmaceutical
US8455500B2 (en) 2009-10-30 2013-06-04 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisoxazole derivative
CA2785674A1 (en) 2009-12-25 2011-06-30 Mochida Pharmaceutical Co., Ltd. Novel 3-hydroxy-5-arylisothiazole derivative
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8703758B2 (en) 2010-04-27 2014-04-22 Takeda Pharmaceutical Company Limited Bicyclic compound
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
AU2011266099B2 (en) 2010-06-16 2014-09-11 Takeda Pharmaceutical Company Limited Crystal of amide compound
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US20130184272A1 (en) 2010-09-17 2013-07-18 Takeda Pharmaceutical Company Limited Diabetes therapeutic agent
WO2012046869A1 (ja) 2010-10-08 2012-04-12 持田製薬株式会社 環状アミド誘導体
US8729102B2 (en) 2010-11-30 2014-05-20 Takeda Pharmaceutical Company Limited Bicyclic compound
JP5853317B2 (ja) 2010-12-01 2016-02-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インダニルオキシジヒドロベンゾフラニル酢酸
JP5945545B2 (ja) * 2011-02-17 2016-07-05 武田薬品工業株式会社 光学活性なジヒドロベンゾフラン誘導体の製造法
EP2694465A4 (en) 2011-04-08 2015-03-18 Univ Syddansk SUBSTITUTED ORTHOFLUOR COMPOUNDS FOR THE TREATMENT OF METABOLISM DISEASES
US8557766B2 (en) 2011-04-27 2013-10-15 Mochida Pharmaceutical Co., Ltd. 3-hydroxyisothiazole 1-oxide derivatives
AU2012248627A1 (en) 2011-04-28 2013-11-14 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103012343B (zh) * 2011-09-26 2015-04-08 上海恒瑞医药有限公司 稠合环类衍生物、其制备方法及其在医药上的应用
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2853221A1 (en) 2011-10-24 2013-05-02 Tohru Yamashita Bicyclic compound
WO2013105676A1 (en) 2012-01-12 2013-07-18 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists
AU2012365706B2 (en) * 2012-01-12 2015-08-20 Jiangsu Hengrui Medicine Co., Ltd. Polycyclic derivatives, preparation method and medical uses thereof
GB2498968A (en) * 2012-02-01 2013-08-07 Prosidion Ltd Pharmaceutical combination of a GPR119 agonist and a GPR40 agonist
JP6095580B2 (ja) 2012-02-13 2017-03-15 武田薬品工業株式会社 芳香環化合物
JP6121339B2 (ja) * 2012-02-13 2017-04-26 武田薬品工業株式会社 芳香環化合物
WO2013122260A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
CA2864990C (en) 2012-02-24 2021-03-02 Nobuyuki Takakura Benzofuran and benzothiophene compounds for the inhibition of ghrelin o-acyltranferase (goat)
MX2014010272A (es) * 2012-02-28 2015-08-14 Piramal Entpr Ltd Derivados del acido fenil alcanoico como agonistas gpr.
US8642585B2 (en) * 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
CN104350040B (zh) 2012-03-29 2016-06-01 武田药品工业株式会社 芳环化合物
US8809376B2 (en) 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
EP2848622A4 (en) 2012-05-10 2015-11-04 Takeda Pharmaceutical Aromatic ring compound
JPWO2013168759A1 (ja) 2012-05-10 2016-01-07 武田薬品工業株式会社 芳香環化合物
JP6122879B2 (ja) 2012-06-05 2017-04-26 武田薬品工業株式会社 固形製剤
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
CN103958480B (zh) 2012-09-04 2016-04-06 上海恒瑞医药有限公司 咪唑啉类衍生物、其制备方法及其在医药上的应用
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
TWI692469B (zh) 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
PT2920165T (pt) 2012-11-16 2016-12-20 Bristol Myers Squibb Co Moduladores de diidropirazol gpr40
WO2014082918A1 (en) 2012-11-28 2014-06-05 Boehringer Ingelheim International Gmbh New indanyloxydihydrobenzofuranylacetic acids
JP6283862B2 (ja) * 2012-12-07 2018-02-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規インダニルオキシジヒドロベンゾフラニル酢酸
EP2953681B1 (en) 2013-02-06 2017-03-15 Boehringer Ingelheim International GmbH New indanyloxydihydrobenzofuranylacetic acids
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
ES2709195T3 (es) 2013-02-28 2019-04-15 Tiumbio Co Ltd Compuesto tricíclico y uso del mismo
CN103145663B (zh) * 2013-03-01 2016-03-23 上海高准医药有限公司 (s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物，其制备方法及其在医药上的应用
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
CN104059039B (zh) * 2013-03-22 2017-03-15 正大天晴药业集团股份有限公司 具有gpr40受体功能调节作用的稠环化合物
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
AR096041A1 (es) 2013-04-17 2015-12-02 Piramal Entpr Ltd Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg
WO2014187343A1 (zh) * 2013-05-22 2014-11-27 四川海思科制药有限公司 苯并呋喃衍生物、其制备方法及其在医药上的应用
CN104250238B (zh) * 2013-06-25 2017-12-26 南京圣和药业股份有限公司 Gpr40激动剂及其应用
CN104250239B (zh) * 2013-06-29 2016-09-07 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
CN104507921B (zh) * 2013-07-02 2017-02-22 四川海思科制药有限公司 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
CA2917490A1 (en) 2013-07-09 2015-01-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
SI3031799T1 (en) 2013-08-09 2018-07-31 Takeda Pharmaceutical Company Limited Aromatic compound
CN104370864B (zh) * 2013-08-14 2016-04-13 成都苑东生物制药股份有限公司 一种2-(6-羟基-2,3-二氢苯并呋喃-3-基)乙腈化合物和以该化合物制备tak-875药物的方法
WO2015032328A1 (zh) * 2013-09-03 2015-03-12 四川海思科制药有限公司 茚满衍生物及其制备方法和在医药上的应用
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104592211B (zh) * 2013-10-31 2018-10-16 广东东阳光药业有限公司 联苯类化合物及其用途
EA201690888A1 (ru) 2013-11-14 2016-10-31 Кадила Хелзкэр Лимитед Новые гетероциклические соединения
EP3068768B1 (en) 2013-11-15 2019-07-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104650055A (zh) * 2013-11-22 2015-05-27 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN105001212B (zh) * 2014-04-16 2018-01-16 江苏柯菲平医药股份有限公司 稠环化合物及其制备方法和应用
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3177285B1 (en) 2014-08-08 2020-09-23 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
EP3177287B1 (en) 2014-08-08 2022-02-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
CN104177320B (zh) * 2014-08-27 2016-03-02 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
DK3207928T3 (da) * 2014-10-17 2021-04-26 Hyundai Pharm Co Ltd Sammensat præparat, der indeholder hidtil ukendt 3-(4-(benzyloxy)phenyl)hex-4-inonsyrederivat og en anden aktiv bestanddel, til forebyggelse eller behandling af metaboliske sygdomme
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
CN105418563B (zh) * 2015-12-28 2017-11-10 山东大学 Tak‑875类似物及其制备方法与应用
EP3436003B1 (en) 2016-03-29 2023-08-23 Merck Sharp & Dohme LLC Antidiabetic bicyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
US10913720B2 (en) 2017-01-26 2021-02-09 Boehringer Ingelheim International Gmbh Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110248929B (zh) 2017-01-26 2023-05-12 勃林格殷格翰国际有限公司 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途
CN110177773B (zh) 2017-01-26 2023-08-25 勃林格殷格翰国际有限公司 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
EP3573969A1 (en) 2017-01-26 2019-12-04 Boehringer Ingelheim International GmbH Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110300755B (zh) 2017-02-08 2022-10-04 勃林格殷格翰国际有限公司 茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物
JOP20180029A1 (ar) 2017-03-30 2019-01-30 Takeda Pharmaceuticals Co مركب حلقي غير متجانس
CN110719903A (zh) 2017-03-31 2020-01-21 武田药品工业株式会社 芳族环化合物
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
US11225471B2 (en) 2017-11-16 2022-01-18 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CA3087712A1 (en) 2018-01-08 2019-07-11 Celon Pharma S.A. 3-phenyl-4-hexynoic acid derivatives as gpr40 agonists
BR102019002873A2 (pt) 2018-02-13 2019-09-10 Gilead Sciences Inc inibidores de pd-1/pd-l1
CN110294744A (zh) * 2018-03-21 2019-10-01 中国医学科学院药物研究所 Gpr40受体激动剂、其制法和其药物组合物与用途
MY205468A (en) 2018-03-23 2024-10-22 Carmot Therapeutics Inc Modulators of g-protein coupled receptors
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP6773938B2 (ja) 2018-08-27 2020-10-21 株式会社スコヒアファーマ 安息香酸エステル化合物
WO2020067557A2 (en) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
WO2020067575A1 (en) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
WO2020166662A1 (ja) 2019-02-13 2020-08-20 株式会社ジェクスヴァル 骨疾患の予防または治療用の医薬組成物
WO2022034664A1 (ja) 2020-08-12 2022-02-17 株式会社ジェクスヴァル 骨疾患の予防または治療用の医薬組成物
US20220071925A1 (en) * 2019-02-13 2022-03-10 Gexval Inc. Medicinal composition for preventing or treating bone diseases
ES2986788T3 (es) 2020-02-07 2024-11-12 Gasherbrum Bio Inc Agonistas heterocíclicos de GLP-1
WO2021193984A2 (en) 2020-03-25 2021-09-30 Takeda Pharmaceutical Company Limited Qd dosing of gip receptor agonist peptide compounds and uses thereof
AR121649A1 (es) 2020-03-25 2022-06-22 Takeda Pharmaceuticals Co Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos
WO2022133111A1 (en) * 2020-12-16 2022-06-23 Regents Of The University Of Minnesota Cubanyl biguanide compounds
US20230151074A1 (en) 2021-05-13 2023-05-18 Carmot Therapeutics, Inc. Modulators of g-protein coupled receptors
CN119137124A (zh) 2022-03-09 2024-12-13 加舒布鲁姆生物公司 杂环glp-1激动剂
CN119212993A (zh) 2022-03-21 2024-12-27 加舒布鲁姆生物公司 作为glp-1激动剂用于糖尿病治疗的5,8-二氢-1,7-萘啶衍生物
EP4508047A1 (en) 2022-04-14 2025-02-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024138048A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025006921A1 (en) 2023-06-30 2025-01-02 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025015268A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Modulators of calcitonin receptor and/or amylin receptor activity
WO2025015269A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309324D0 (en) * 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
US5489586A (en) 1994-03-07 1996-02-06 Warner-Lambert Company Method for treating inflammatory disease in humans
US5612330A (en) 1994-03-07 1997-03-18 Warner-Lambert Company Methods for inhibiting and controlling viral growth
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
RU6023U1 (ru) 1997-01-20 1998-02-16 АО "Автоэлектроника" Устройство управления для экономайзера принудительного холостого хода
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
WO1999022735A1 (en) 1997-10-30 1999-05-14 Merck & Co., Inc. Somatostatin agonists
EE200100558A (et) 1999-04-28 2002-12-16 Aventis Pharma Deutschland Gmbh Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
RU11297U1 (ru) 1999-06-16 1999-09-16 Курзанов Евгений Владимирович Установка для выборочного измерения производительности нефтяных источников при групповом учете
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1222182B1 (en) 1999-08-26 2005-11-16 Aventis Pharmaceuticals Inc. Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
WO2001025228A1 (fr) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Derives d'amines
CZ20021604A3 (cs) 1999-11-10 2002-09-11 Takeda Chemical Industries, Ltd. Pětičlenné N-heterocyklické sloučeniny, farmaceutický přípravek a činidlo je obsahující a jejich použití
CA2395414A1 (en) * 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd Condensed purine derivative
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
JP4105949B2 (ja) * 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
RU2340611C2 (ru) 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6653301B2 (en) * 2000-12-21 2003-11-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002068471A2 (en) * 2000-12-21 2002-09-06 Bristol-Myers Squibb Company Nucleic acid molecules and polypeptides for a human cation channel polypeptide
SK11852003A3 (sk) * 2001-03-30 2004-07-07 Pfizer Products Inc. Derivát pyridazinónu ako inhibítor aldózreduktázy a farmaceutický prostriedok, ktorý ho obsahuje
TWI311133B (en) * 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
TW522326B (en) * 2001-08-03 2003-03-01 Inventec Corp Real-time data customer service system and method thereof
US6701066B2 (en) * 2001-10-11 2004-03-02 Micron Technology, Inc. Delivery of solid chemical precursors
US20050245571A1 (en) 2001-10-19 2005-11-03 Hidenori Abe Amine derivative
JP4166024B2 (ja) 2002-03-07 2008-10-15 独立行政法人科学技術振興機構 ２環式化合物およびその製造方法
WO2003095438A1 (en) * 2002-04-26 2003-11-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
AU2003252697A1 (en) * 2002-07-26 2004-02-16 Kyowa Hakko Kogyo Co., Ltd. Cell differentiation inductor
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20070105959A1 (en) * 2003-03-11 2007-05-10 Shinya Kusuda Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
WO2004106276A1 (ja) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
RU2353617C2 (ru) 2003-10-31 2009-04-27 Такеда Фармасьютикал Компани Лимитед Производные пиридина в качестве ингибиторов дипептидилпептидазы iv
PE20050444A1 (es) * 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 ３−（４−ベンジルオキシフェニル）プロパン酸誘導体
CA2551610A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
EP1698624B1 (en) * 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
CA2560111A1 (en) * 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4859665B2 (ja) * 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
JP3689711B1 (ja) 2004-12-24 2005-08-31 極東鋼弦コンクリート振興株式会社 真空グラウト注入方法
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200640862A (en) * 2005-02-25 2006-12-01 Takeda Pharmaceuticals Co Pyridyl acetic acid compounds
PE20080344A1 (es) * 2006-06-27 2008-06-09 Sanofi Aventis Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
TW200811158A (en) * 2006-06-27 2008-03-01 Sanofi Aventis Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application

Also Published As

Publication number Publication date
EP2743268A2 (en) 2014-06-18
ME00535B (me) 2011-10-10
CN103083307A (zh) 2013-05-08
NZ574038A (en) 2011-12-22
US20130267589A1 (en) 2013-10-10
CY1114978T1 (el) 2016-12-14
AR061644A1 (es) 2008-09-10
JP5409757B2 (ja) 2014-02-05
PT2248812E (pt) 2014-03-12
ES2450081T3 (es) 2014-03-21
JO2969B1 (en) 2016-03-15
EP2431367A3 (en) 2012-07-04
GEP20115359B (en) 2011-12-26
ZA200900154B (en) 2010-03-31
US20120046338A1 (en) 2012-02-23
RS52307B (en) 2012-12-31
KR20090027743A (ko) 2009-03-17
MY154798A (en) 2015-07-31
CA2656003C (en) 2014-03-25
SI2041123T1 (sl) 2012-05-31
PT2041123E (pt) 2012-04-09
US8088821B2 (en) 2012-01-03
US20140080891A1 (en) 2014-03-20
JP4917634B2 (ja) 2012-04-18
BRPI0713378A8 (pt) 2018-01-02
HRP20140201T1 (hr) 2014-04-11
MX2008016274A (es) 2009-01-15
JP2012062320A (ja) 2012-03-29
CA2838448A1 (en) 2008-01-03
EP2248812B1 (en) 2013-12-25
CN102731451A (zh) 2012-10-17
MA30537B1 (fr) 2009-06-01
TWI354668B (en) 2011-12-21
HK1131126A1 (en) 2010-01-15
CN101616913B (zh) 2013-01-23
DK2248812T3 (da) 2014-03-10
IL195947A0 (en) 2009-09-01
AU2007265966A1 (en) 2008-01-03
EP2431367A2 (en) 2012-03-21
IL195947A (en) 2013-07-31
CA2656003A1 (en) 2008-01-03
WO2008001931A2 (en) 2008-01-03
US8598226B2 (en) 2013-12-03
PL2041123T3 (pl) 2012-09-28
RS53230B (en) 2014-08-29
HRP20120333T1 (hr) 2012-05-31
CO6160234A2 (es) 2010-05-20
EP2248812A2 (en) 2010-11-10
CN101616913A (zh) 2009-12-30
US20100004312A1 (en) 2010-01-07
US7732626B2 (en) 2010-06-08
DK2041123T3 (da) 2012-05-07
WO2008001931A3 (en) 2009-09-11
AU2007265966B2 (en) 2012-05-17
US8492430B2 (en) 2013-07-23
DK2248812T5 (da) 2015-01-26
EP2041123A2 (en) 2009-04-01
CL2007001873A1 (es) 2008-01-04
JP4401428B2 (ja) 2010-01-20
JP2009280595A (ja) 2009-12-03
JP2009542580A (ja) 2009-12-03
BRPI0713378A2 (pt) 2012-04-03
ATE543815T1 (de) 2012-02-15
RU2009102515A (ru) 2010-08-10
CY1112705T1 (el) 2016-02-10
EP2041123B9 (en) 2013-01-02
ES2379661T3 (es) 2012-04-30
SI2248812T1 (sl) 2014-04-30
EP2743268A3 (en) 2014-10-08
CN102731451B (zh) 2015-07-29
PL2248812T3 (pl) 2014-07-31
CR10564A (es) 2012-06-18
KR101058772B1 (ko) 2011-08-24
EP2041123B1 (en) 2012-02-01
PE20080993A1 (es) 2008-10-06
US20100197761A1 (en) 2010-08-05
EP2248812A3 (en) 2011-03-16
RU2444521C2 (ru) 2012-03-10
TW200811125A (en) 2008-03-01
CN103070854A (zh) 2013-05-01
UA95296C2 (uk) 2011-07-25

Similar Documents

Publication Publication Date Title
NO20090235L (no) Kondenserte sykliske forbindelser
NO20091948L (no) Indol forbindelse
EA200970746A1 (ru) Конденсированные циклические соединения в качестве частичных агонистов ppar-гамма
NO20081196L (no) Terapeutisk middel for diabetes
EA201071032A1 (ru) Гетероциклическое соединение
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
EA200900877A1 (ru) Пиперидиновые агонисты gpcr
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
NO20084307L (no) Heterocykliske GPCR agonister
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
NO20084278L (no) Bezothiazol derivatives as beta2 adrenoreceptor agonists
EP1873144A4 (en) CONDENSED HETEROCYCLIC COMPOUND
NO20081454L (no) Met-kinaseinhibitorer
NO20083717L (no) Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer
UY33756A (es) Compuesto biciclico
NO20083026L (no) Terapeutisk middel for diabetes
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
EA201071180A1 (ru) Конденсированные циклические соединения и их применение
NO20071222L (no) Benzamidforbindelser.
NO20090173L (no) Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
WO2007017892A3 (en) Novel compounds as glp-i agonists
CL2014001377A1 (es) Compuestos derivados de n-(4-quinolilmetil)-sulfonamida, sus n-oxido o sus sales; composicion que los comprende, util para el tratamiento de infeccion por helmintos.
NO20080553L (no) Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander
NO20081948L (no) Heksahydro-cykloheptapyrazol cannabinoide modulatorer